Hypoactive Sexual Desire Disorder (HSDD)
Bremelanotide (brand name: Vyleesi) is a drug approved by the FDA to treat a lack of sexual desire (hypoactive sexual desire disorder) in premenopausal women.
Flibanserin (brand name: Addyi) is the first drug approved by the U.S. Food and Drug Administration (FDA) to treat lack of sexual desire (Hypoactive Sexual Desire Disorder) in premenopausal women.
“My doctor prescribed me Addyi for HSDD. I cannot afford it and my insurance does not cover it. Are there any other resources to get this medication?”
Rather than a failed “fix-all” pill, NWHN encourages rigorous research be conducted exploring the causes of women’s sexual problems, possible solutions, and what, if anything, might constitute “normal” when it comes to women’s sexuality.
The National Women’s Health Network is warning all women about the health risks of the new “pink pill” – known as flibanserin and branded as Addyi – alleged to boost female libido. Rather than rely on drug company marketing, NWHN recommends that women educate themselves and pass on the pink pill.
FOR IMMEDIATE RELEASE Contact: Christina Cherel at email@example.com or (202) 682-2640
Learn about Addyi (flibanserin) and Vyleesi (bremelanotide), FDA-approved drugs designed to treat hypoactive sexual desire disorder (HSDD) in premenopausal women.
FOR IMMEDIATE RELEASE
Contact: Cindy Pearson at 301-938-0356 or Coco Jervis at 202-407-0788
Food and Drug Administration Scientific Workshop on Female Sexual Interest/Arousal Disorder